包含1-[6-(嗎啉-4-基)嘧啶-4-基]-4-(1H-1,2,3-三唑-1-基)-1H-吡唑-5-醇鈉之醫藥劑型农业专利-农业专业知识服务系统

发明人:: NEUMANN, HEIKE,纽曼　海克,紐曼　海克,BENKE, KLAUS,班克　克劳斯,班克　克勞斯,FORMELL, MICHAEL,弗麦尔　麦可,弗麥爾　麥可,WINTER, GABRIELE,温特　盖柏里尔,溫特　蓋柏里爾,纽曼海克,紐曼海克,班克克劳斯,班克克勞斯,弗麦尔麦可,弗麥爾麥可,温特盖柏里尔,溫特蓋柏里爾

摘要：: The present invention relates relates to solid pharmaceutical dosage forms for oral administration comprising sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1 H-pyrazol-5-olate (active ingredient (I)), characterized in that the active ingredient (I) is released, and also methods for the preparation thereof, use thereof as medicaments, and also use thereof for prophylaxis, secondary prophylaxis or treatment of disorders, particularly cardiovascular disorders, heart failure, anaemia, chronic renal disorders and renal insufficiency.本發明關於經口投予的包含1-[6-(嗎啉-4-基)嘧啶-4-基]-4-(1H-1,2,3-三唑-1-基)-1H-吡唑-5-醇鈉(活性成分(I))之固體醫藥劑型，其特徵在於釋放活性成分(I)，及亦關於其製備方法、其用作為藥劑之用途、及其預防、二次預防或治療病症之用途，特別用於心血管病症、心臟衰竭、貧血、慢性腎功能失調和腎功能不全。